世界の非ホジキンリンパ腫治療市場2023年〜2027年

◆英語タイトル:Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027

Technavioが発行した調査報告書(IRTNTR70886-23)◆商品コード:IRTNTR70886-23
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年2月6日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他地域
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

テックナビオ社の本調査資料では、世界の非ホジキンリンパ腫治療市場規模が2023年から2027年の間に5,427.51百万ドルに到達し、予測期間中の年平均成長率は8.14%になると展望しています。本書は、非ホジキンリンパ腫治療の世界市場について徹底的に調査し、市場の現状や動向をまとめた資料です。エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局、その他)分析、治療別(免疫療法、標的療法、化学療法)分析、顧客状況、地域別(北米、ヨーロッパ、アジア、アメリカ、イギリス、ドイツ、中国、カナダ、その他地域)分析、企業分析などを整理しています。本資料内には、AstraZeneca Plc、Baxter International Inc.、Bayer AG、BeiGene Ltd.、Biogen Inc.、Bristol Myers Squibb Co.、Eisai Co. Ltd.、Eli Lilly and Co.、F. Hoffmann La Roche Ltd.、Gilead Sciences Inc.、GlaxoSmithKline Plc、Johnson and Johnson Services Inc.、Merck KGaA、Novartis AG、Pfizer Inc.、Seagen Inc.、Spectrum Pharmaceuticals Inc.、Takeda Pharmaceutical Co. Ltd.、Teva Pharmaceutical Industries Ltd.Xなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界の非ホジキンリンパ腫治療市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- その他の市場規模
・世界の非ホジキンリンパ腫治療市場規模:治療別
- 免疫療法の市場規模
- 標的療法の市場規模
- 化学療法の市場規模
・顧客状況
・世界の非ホジキンリンパ腫治療市場規模:地域別
- 北米の非ホジキンリンパ腫治療市場規模
- ヨーロッパの非ホジキンリンパ腫治療市場規模
- アジアの非ホジキンリンパ腫治療市場規模
- アメリカの非ホジキンリンパ腫治療市場規模
- イギリスの非ホジキンリンパ腫治療市場規模
- ドイツの非ホジキンリンパ腫治療市場規模
- 中国の非ホジキンリンパ腫治療市場規模
- カナダの非ホジキンリンパ腫治療市場規模
- その他地域の非ホジキンリンパ腫治療市場規模
・成長要因・課題・動向
・企業状況
・企業分析

テックナビオ社は、利益、価格、競争、プロモーションなどの主要なパラメーターを調査・分析することで、また様々なソースからのデータを調査、統合、および合計することにより、非ホジキンリンパ腫治療市場の詳しい全体像を示します。主な産業のインフルエンサーを特定することにより、市場の多様な側面を提示します。提示されたデータは包括的​​かつ信頼性があり、一次/二次の広範囲な調査の結果です。 テックナビオ社の市場調査資料は、正確な非ホジキンリンパ腫治療市場の成長を予想するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選択方法、また分析を整理しています。

非ホジキンリンパ腫治療市場 2023-2027

Technavio社は、非ホジキンリンパ腫治療市場をモニターしており、2022年から2027年にかけて5427.51百万ドルの成長が予測され、予測期間中のCAGRは8.14%で加速すると予測しています。当レポートでは、非ホジキンリンパ腫治療市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。最近の承認や強力なパイプライン、高齢者人口の増加、特効薬指定などが市場を牽引しています。

Technavioの非ホジキンリンパ腫治療市場は以下のように区分されます:

・流通チャネル別:
- 病院薬局
- 小売薬局
- オンライン薬局
- その他

・療法別:
- 免疫療法
- 標的療法
- 化学療法

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間における非ホジキンリンパ腫治療市場の成長を促進する主な理由の一つとして、研究助成金と資金提供を挙げています。また、がんに対する意識の高まりや、患者支援プログラムおよび償還金の増加は、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、非ホジキンリンパ腫治療市場について以下の分野をカバーしています:
- 非ホジキンリンパ腫治療市場のサイジング
- 非ホジキンリンパ腫治療市場予測
- 非ホジキンリンパ腫治療市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltdなどの企業情報が含まれています。また、非ホジキンリンパ腫治療市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global non-hodgkin lymphoma therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global non-hodgkin lymphoma therapeutics market 2017 – 2021 ($ million)
o 4.2 Therapy Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Distribution Channel
o 6.1 Market segments
o Exhibit 30: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 6.2 Comparison by Distribution Channel
o Exhibit 32: Chart on Comparison by Distribution Channel
o Exhibit 33: Data Table on Comparison by Distribution Channel
o 6.3 Hospital pharmacy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o 6.4 Retail pharmacy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o 6.5 Online pharmacy – Market size and forecast 2022-2027
o Exhibit 42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
o 6.6 Others – Market size and forecast 2022-2027
o Exhibit 46: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.7 Market opportunity by Distribution Channel
o Exhibit 50: Market opportunity by Distribution Channel ($ million)
• 7 Market Segmentation by Therapy
o 7.1 Market segments
o Exhibit 51: Chart on Therapy – Market share 2022-2027 (%)
o Exhibit 52: Data Table on Therapy – Market share 2022-2027 (%)
o 7.2 Comparison by Therapy
o Exhibit 53: Chart on Comparison by Therapy
o Exhibit 54: Data Table on Comparison by Therapy
o 7.3 Immunotherapy – Market size and forecast 2022-2027
o Exhibit 55: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
o 7.4 Targeted therapy – Market size and forecast 2022-2027
o Exhibit 59: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
o 7.5 Chemotherapy – Market size and forecast 2022-2027
o Exhibit 63: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Therapy
o Exhibit 67: Market opportunity by Therapy ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 69: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 71: Chart on Geographic comparison
o Exhibit 72: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 73: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 89: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 Canada – Market size and forecast 2022-2027
o Exhibit 105: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 106: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 107: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 108: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 109: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 110: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 112: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 113: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 114: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 115: Matrix on vendor position and classification
o 12.3 AstraZeneca Plc
o Exhibit 116: AstraZeneca Plc – Overview
o Exhibit 117: AstraZeneca Plc – Product / Service
o Exhibit 118: AstraZeneca Plc – Key news
o Exhibit 119: AstraZeneca Plc – Key offerings
o 12.4 BeiGene Ltd.
o Exhibit 120: BeiGene Ltd. – Overview
o Exhibit 121: BeiGene Ltd. – Business segments
o Exhibit 122: BeiGene Ltd. – Key offerings
o Exhibit 123: BeiGene Ltd. – Segment focus
o 12.5 Biogen Inc.
o Exhibit 124: Biogen Inc. – Overview
o Exhibit 125: Biogen Inc. – Product / Service
o Exhibit 126: Biogen Inc. – Key offerings
o 12.6 Bristol Myers Squibb Co.
o Exhibit 127: Bristol Myers Squibb Co. – Overview
o Exhibit 128: Bristol Myers Squibb Co. – Product / Service
o Exhibit 129: Bristol Myers Squibb Co. – Key news
o Exhibit 130: Bristol Myers Squibb Co. – Key offerings
o 12.7 Eisai Co. Ltd.
o Exhibit 131: Eisai Co. Ltd. – Overview
o Exhibit 132: Eisai Co. Ltd. – Business segments
o Exhibit 133: Eisai Co. Ltd. – Key offerings
o Exhibit 134: Eisai Co. Ltd. – Segment focus
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 135: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 136: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 137: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 138: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 139: F. Hoffmann La Roche Ltd. – Segment focus
o 12.9 Gilead Sciences Inc.
o Exhibit 140: Gilead Sciences Inc. – Overview
o Exhibit 141: Gilead Sciences Inc. – Product / Service
o Exhibit 142: Gilead Sciences Inc. – Key news
o Exhibit 143: Gilead Sciences Inc. – Key offerings
o 12.10 GlaxoSmithKline Plc
o Exhibit 144: GlaxoSmithKline Plc – Overview
o Exhibit 145: GlaxoSmithKline Plc – Business segments
o Exhibit 146: GlaxoSmithKline Plc – Key offerings
o Exhibit 147: GlaxoSmithKline Plc – Segment focus
o 12.11 Johnson and Johnson Services Inc.
o Exhibit 148: Johnson and Johnson Services Inc. – Overview
o Exhibit 149: Johnson and Johnson Services Inc. – Business segments
o Exhibit 150: Johnson and Johnson Services Inc. – Key news
o Exhibit 151: Johnson and Johnson Services Inc. – Key offerings
o Exhibit 152: Johnson and Johnson Services Inc. – Segment focus
o 12.12 Merck KGaA
o Exhibit 153: Merck KGaA – Overview
o Exhibit 154: Merck KGaA – Business segments
o Exhibit 155: Merck KGaA – Key news
o Exhibit 156: Merck KGaA – Key offerings
o Exhibit 157: Merck KGaA – Segment focus
o 12.13 Novartis AG
o Exhibit 158: Novartis AG – Overview
o Exhibit 159: Novartis AG – Business segments
o Exhibit 160: Novartis AG – Key offerings
o Exhibit 161: Novartis AG – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 162: Pfizer Inc. – Overview
o Exhibit 163: Pfizer Inc. – Product / Service
o Exhibit 164: Pfizer Inc. – Key news
o Exhibit 165: Pfizer Inc. – Key offerings
o 12.15 Seagen Inc.
o Exhibit 166: Seagen Inc. – Overview
o Exhibit 167: Seagen Inc. – Product / Service
o Exhibit 168: Seagen Inc. – Key offerings
o 12.16 Spectrum Pharmaceuticals Inc.
o Exhibit 169: Spectrum Pharmaceuticals Inc. – Overview
o Exhibit 170: Spectrum Pharmaceuticals Inc. – Product / Service
o Exhibit 171: Spectrum Pharmaceuticals Inc. – Key offerings
o 12.17 Teva Pharmaceutical Industries Ltd.
o Exhibit 172: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 173: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 174: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 175: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 176: Teva Pharmaceutical Industries Ltd. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 177: Inclusions checklist
o Exhibit 178: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 179: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 180: Research methodology
o Exhibit 181: Validation techniques employed for market sizing
o Exhibit 182: Information sources
o 13.5 List of abbreviations
o Exhibit 183: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits6: Executive Summary – Chart on Market Segmentation by Therapy
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global non-hodgkin lymphoma therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits31: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Distribution Channel
Exhibits33: Data Table on Comparison by Distribution Channel
Exhibits34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits50: Market opportunity by Distribution Channel ($ million)
Exhibits51: Chart on Therapy – Market share 2022-2027 (%)
Exhibits52: Data Table on Therapy – Market share 2022-2027 (%)
Exhibits53: Chart on Comparison by Therapy
Exhibits54: Data Table on Comparison by Therapy
Exhibits55: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits63: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits67: Market opportunity by Therapy ($ million)
Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits69: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits71: Chart on Geographic comparison
Exhibits72: Data Table on Geographic comparison
Exhibits73: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits105: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits106: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits107: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits108: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits109: Market opportunity By Geographical Landscape ($ million)
Exhibits110: Impact of drivers and challenges in 2022 and 2027
Exhibits111: Overview on Criticality of inputs and Factors of differentiation
Exhibits112: Overview on factors of disruption
Exhibits113: Impact of key risks on business
Exhibits114: Vendors covered
Exhibits115: Matrix on vendor position and classification
Exhibits116: AstraZeneca Plc – Overview
Exhibits117: AstraZeneca Plc – Product / Service
Exhibits118: AstraZeneca Plc – Key news
Exhibits119: AstraZeneca Plc – Key offerings
Exhibits120: BeiGene Ltd. – Overview
Exhibits121: BeiGene Ltd. – Business segments
Exhibits122: BeiGene Ltd. – Key offerings
Exhibits123: BeiGene Ltd. – Segment focus
Exhibits124: Biogen Inc. – Overview
Exhibits125: Biogen Inc. – Product / Service
Exhibits126: Biogen Inc. – Key offerings
Exhibits127: Bristol Myers Squibb Co. – Overview
Exhibits128: Bristol Myers Squibb Co. – Product / Service
Exhibits129: Bristol Myers Squibb Co. – Key news
Exhibits130: Bristol Myers Squibb Co. – Key offerings
Exhibits131: Eisai Co. Ltd. – Overview
Exhibits132: Eisai Co. Ltd. – Business segments
Exhibits133: Eisai Co. Ltd. – Key offerings
Exhibits134: Eisai Co. Ltd. – Segment focus
Exhibits135: F. Hoffmann La Roche Ltd. – Overview
Exhibits136: F. Hoffmann La Roche Ltd. – Business segments
Exhibits137: F. Hoffmann La Roche Ltd. – Key news
Exhibits138: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits139: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits140: Gilead Sciences Inc. – Overview
Exhibits141: Gilead Sciences Inc. – Product / Service
Exhibits142: Gilead Sciences Inc. – Key news
Exhibits143: Gilead Sciences Inc. – Key offerings
Exhibits144: GlaxoSmithKline Plc – Overview
Exhibits145: GlaxoSmithKline Plc – Business segments
Exhibits146: GlaxoSmithKline Plc – Key offerings
Exhibits147: GlaxoSmithKline Plc – Segment focus
Exhibits148: Johnson and Johnson Services Inc. – Overview
Exhibits149: Johnson and Johnson Services Inc. – Business segments
Exhibits150: Johnson and Johnson Services Inc. – Key news
Exhibits151: Johnson and Johnson Services Inc. – Key offerings
Exhibits152: Johnson and Johnson Services Inc. – Segment focus
Exhibits153: Merck KGaA – Overview
Exhibits154: Merck KGaA – Business segments
Exhibits155: Merck KGaA – Key news
Exhibits156: Merck KGaA – Key offerings
Exhibits157: Merck KGaA – Segment focus
Exhibits158: Novartis AG – Overview
Exhibits159: Novartis AG – Business segments
Exhibits160: Novartis AG – Key offerings
Exhibits161: Novartis AG – Segment focus
Exhibits162: Pfizer Inc. – Overview
Exhibits163: Pfizer Inc. – Product / Service
Exhibits164: Pfizer Inc. – Key news
Exhibits165: Pfizer Inc. – Key offerings
Exhibits166: Seagen Inc. – Overview
Exhibits167: Seagen Inc. – Product / Service
Exhibits168: Seagen Inc. – Key offerings
Exhibits169: Spectrum Pharmaceuticals Inc. – Overview
Exhibits170: Spectrum Pharmaceuticals Inc. – Product / Service
Exhibits171: Spectrum Pharmaceuticals Inc. – Key offerings
Exhibits172: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits173: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits174: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits175: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits176: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits177: Inclusions checklist
Exhibits178: Exclusions checklist
Exhibits179: Currency conversion rates for US$
Exhibits180: Research methodology
Exhibits181: Validation techniques employed for market sizing
Exhibits182: Information sources
Exhibits183: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の非ホジキンリンパ腫治療市場2023年〜2027年(Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆